Cargando…
Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis
OBJECTIVES: To model the potential health gains and cost-effectiveness of a mandatory limit of industrial trans fatty acids (iTFA) in Kenyan foods. DESIGN: Multiple cohort proportional multistate life table model, incorporating existing data from the Global Burden of Disease study, pooled analyses o...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583044/ https://www.ncbi.nlm.nih.gov/pubmed/37848268 http://dx.doi.org/10.1136/bmjgh-2023-012692 |
_version_ | 1785122472257912832 |
---|---|
author | Marklund, Matti Aminde, Leopold N Wanjau, Mary Njeri Huang, Liping Awuor, Celine Steele, Lindsay Cobb, Laura K Veerman, J Lennert Wu, Jason HY |
author_facet | Marklund, Matti Aminde, Leopold N Wanjau, Mary Njeri Huang, Liping Awuor, Celine Steele, Lindsay Cobb, Laura K Veerman, J Lennert Wu, Jason HY |
author_sort | Marklund, Matti |
collection | PubMed |
description | OBJECTIVES: To model the potential health gains and cost-effectiveness of a mandatory limit of industrial trans fatty acids (iTFA) in Kenyan foods. DESIGN: Multiple cohort proportional multistate life table model, incorporating existing data from the Global Burden of Disease study, pooled analyses of observational studies and peer-reviewed evidence of healthcare and policy implementation costs. SETTING: Kenya. PARTICIPANTS: Adults aged ≥20 years at baseline (n=50 million). INTERVENTION: A mandatory iTFA limit (≤2% of all fats) in the Kenyan food supply compared with a base case scenario of maintaining current trans fat intake. MAIN OUTCOME MEASURES: Averted ischaemic heart disease (IHD) events and deaths, health-adjusted life years; healthcare costs; policy implementation costs; net costs; and incremental cost-effectiveness ratio. RESULTS: Over the first 10 years, the intervention was estimated to prevent ~1900 (95% uncertainty interval (UI): 1714; 2148) IHD deaths and ~17 000 (95% UI: 15 475; 19 551) IHD events, and to save ~US$50 million (95% UI: 44; 56). The corresponding estimates over the lifespan of the model population were ~49 000 (95% UI: 43 775; 55 326) IHD deaths prevented, ~113 000 (95% UI: 100 104; 127 969) IHD events prevented and some ~US$300 million (256; 331) saved. Policy implementation costs were estimated as ~US$9 million over the first 10 years and ~US$20 million over the population lifetime. The intervention was estimated to be cost saving regardless of the time horizon. Findings were robust across multiple sensitivity analyses. CONCLUSIONS: Findings support policy action for a mandatory iTFA limit as a cost-saving strategy to avert IHD events and deaths in Kenya. |
format | Online Article Text |
id | pubmed-10583044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-105830442023-10-19 Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis Marklund, Matti Aminde, Leopold N Wanjau, Mary Njeri Huang, Liping Awuor, Celine Steele, Lindsay Cobb, Laura K Veerman, J Lennert Wu, Jason HY BMJ Glob Health Original Research OBJECTIVES: To model the potential health gains and cost-effectiveness of a mandatory limit of industrial trans fatty acids (iTFA) in Kenyan foods. DESIGN: Multiple cohort proportional multistate life table model, incorporating existing data from the Global Burden of Disease study, pooled analyses of observational studies and peer-reviewed evidence of healthcare and policy implementation costs. SETTING: Kenya. PARTICIPANTS: Adults aged ≥20 years at baseline (n=50 million). INTERVENTION: A mandatory iTFA limit (≤2% of all fats) in the Kenyan food supply compared with a base case scenario of maintaining current trans fat intake. MAIN OUTCOME MEASURES: Averted ischaemic heart disease (IHD) events and deaths, health-adjusted life years; healthcare costs; policy implementation costs; net costs; and incremental cost-effectiveness ratio. RESULTS: Over the first 10 years, the intervention was estimated to prevent ~1900 (95% uncertainty interval (UI): 1714; 2148) IHD deaths and ~17 000 (95% UI: 15 475; 19 551) IHD events, and to save ~US$50 million (95% UI: 44; 56). The corresponding estimates over the lifespan of the model population were ~49 000 (95% UI: 43 775; 55 326) IHD deaths prevented, ~113 000 (95% UI: 100 104; 127 969) IHD events prevented and some ~US$300 million (256; 331) saved. Policy implementation costs were estimated as ~US$9 million over the first 10 years and ~US$20 million over the population lifetime. The intervention was estimated to be cost saving regardless of the time horizon. Findings were robust across multiple sensitivity analyses. CONCLUSIONS: Findings support policy action for a mandatory iTFA limit as a cost-saving strategy to avert IHD events and deaths in Kenya. BMJ Publishing Group 2023-10-17 /pmc/articles/PMC10583044/ /pubmed/37848268 http://dx.doi.org/10.1136/bmjgh-2023-012692 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Marklund, Matti Aminde, Leopold N Wanjau, Mary Njeri Huang, Liping Awuor, Celine Steele, Lindsay Cobb, Laura K Veerman, J Lennert Wu, Jason HY Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis |
title | Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis |
title_full | Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis |
title_fullStr | Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis |
title_full_unstemmed | Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis |
title_short | Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis |
title_sort | estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in kenya: cost-effectiveness analysis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583044/ https://www.ncbi.nlm.nih.gov/pubmed/37848268 http://dx.doi.org/10.1136/bmjgh-2023-012692 |
work_keys_str_mv | AT marklundmatti estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis AT amindeleopoldn estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis AT wanjaumarynjeri estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis AT huangliping estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis AT awuorceline estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis AT steelelindsay estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis AT cobblaurak estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis AT veermanjlennert estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis AT wujasonhy estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis |